Idź do Transakcji
Usługi finansowe | Opieka zdrowotna

SulAmérica and Rede D’Or São Luiz have announced a combination

SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.

SulAmérica is one of the largest insurance companies in Brazil and operates in the health and dental insurance, life and pension plans, and asset management sectors. The company was founded in 1895 and is headquartered in Rio de Janeiro, Brazil.

Rede D’Or is the largest integrated healthcare network in Brazil, operating in the health sector, with an extensive network of private hospitals.

One of Oaklins’ teams in Brazil acted as the sole financial advisor to SulAmérica on its combination with Rede D’Or São Luiz S.A. The transaction will be submitted for approvals at shareholders’ meetings of both companies and to relevant regulatory agencies. Once the closing date is defined the companies will inform the market.

Porozmawiaj z zespołem obsługi transakcji

Richard Rainer

Partner Zarządzający
São Paulo, Brazylia
Oaklins Olimpia Partners

Irajá Guimarães

Partner
São Paulo, Brazylia
Oaklins Olimpia Partners

Sara Rezende

Partner
São Paulo, Brazylia
Oaklins Olimpia Partners

Powiązane transakcje

Medicija has acquired Saulės Šeimos Medicinos Centras
Opieka zdrowotna

Medicija has acquired Saulės Šeimos Medicinos Centras

Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.

Więcej informacji
Quimpharma has completed the divestiture of a product portfolio to Megalabs
Opieka zdrowotna

Quimpharma has completed the divestiture of a product portfolio to Megalabs

Quimpharma has completed the divestiture of a product portfolio to Megalabs México.

Więcej informacji
IXICO has completed a fundraising
Opieka zdrowotna

IXICO has completed a fundraising

IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.

Więcej informacji